Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens.
R&D:CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining CRISPR perturbation with single-cell sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these screens.
Services:Myllia offers CRISPR screens with single-cell transcriptomics readout in advanced and challenging cellular models, like primary T-cells. The results of such screens have a much higher chance of being physiologically relevant in the human body than data produced in commonly used immortalized cancer lines. Myllia’s unique technology supports identification of the critical genes and pathways driving certain disease states or impacting on the disease phenotype.
Am Kanal 27
Wien
Vienna
Contact: Thomas Moser (CEO)
Telephone: +43 1 9346880 200
Email: office@myllia.com
Website